Looks like you clickedhttps://www.businesswire.com/news/home/20240313169337/en/U.S.-FDA-Approves-Bristol-Myers-Squibb’s-Breyanzi®-as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-CLL-or-Small-Lymphocytic-Lymphoma-SLL
If you do not want to visit that page, you can close this browser tab.
